128 related articles for article (PubMed ID: 20005117)
1. Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
Nikpour M; Sadeghian H; Saberi MR; Nick RS; Seyedi SM; Hosseini A; Parsaee H; Bozorg AT
Bioorg Med Chem; 2010 Jan; 18(2):855-62. PubMed ID: 20005117
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents.
Sadeghian H; Seyedi SM; Saberi MR; Nick RS; Hosseini A; Bakavoli M; Mansouri SM; Parsaee H
J Enzyme Inhib Med Chem; 2009 Aug; 24(4):918-29. PubMed ID: 19555170
[TBL] [Abstract][Full Text] [Related]
3. Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria.
Mansouri SM; Shafiee-Nick R; Parsaee H; Seyedi SM; Saberi MR; Sadeghian H
Iran Biomed J; 2008 Apr; 12(2):77-84. PubMed ID: 18506213
[TBL] [Abstract][Full Text] [Related]
4. Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
Duan LM; Yu HY; Li YL; Jia CJ
Bioorg Med Chem; 2015 Sep; 23(18):6111-7. PubMed ID: 26319621
[TBL] [Abstract][Full Text] [Related]
5. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
7. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
[TBL] [Abstract][Full Text] [Related]
8. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.
Gouault N; Martin-Chouly CA; Lugnier C; Cupif JF; Tonnelier A; Feger F; Lagente V; David M
J Pharm Pharmacol; 2004 Aug; 56(8):1029-37. PubMed ID: 15285848
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.
Roma G; Di Braccio M; Grossi G; Piras D; Leoncini G; Bruzzese D; Signorello MG; Fossa P; Mosti L
J Med Chem; 2007 Jun; 50(12):2886-95. PubMed ID: 17500510
[TBL] [Abstract][Full Text] [Related]
12. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones.
Ochiai K; Takita S; Kojima A; Eiraku T; Ando N; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2012 Sep; 22(18):5833-8. PubMed ID: 22884989
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
Cappelli A; Pericot Mohr Gl Gl; Gallelli A; Rizzo M; Anzini M; Vomero S; Mennuni L; Ferrari F; Makovec F; Menziani MC; De Benedetti PG; Giorgi G
J Med Chem; 2004 May; 47(10):2574-86. PubMed ID: 15115399
[TBL] [Abstract][Full Text] [Related]
15. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides.
Anderson AJ; Nicholson JM; Bakare O; Butcher RJ; Wilson TL; Scott KR
Bioorg Med Chem; 2006 Feb; 14(4):997-1006. PubMed ID: 16219468
[TBL] [Abstract][Full Text] [Related]
16. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
Dorigo P; Fraccarollo D; Santostasi G; Maragno I; Floreani M; Borea PA; Mosti L; Sansebastiano L; Fossa P; Orsini F; Benetollo F; Bombieri G
J Med Chem; 1996 Sep; 39(19):3671-83. PubMed ID: 8809156
[TBL] [Abstract][Full Text] [Related]
18. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
[TBL] [Abstract][Full Text] [Related]
19. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
Chen L; Li H; Liu J; Zhang L; Liu H; Jiang H
Bioorg Med Chem; 2007 Nov; 15(21):6763-74. PubMed ID: 17719791
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
Liu H; Maurice DH
Br J Pharmacol; 1998 Dec; 125(7):1501-10. PubMed ID: 9884079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
